Statistics on Biotechnology Use  
Results by sector of operation
Company sector.  Biotechnology results by main variables by whichever Biotechnology activities are the main ones, secondary or a tool necessary for production
Unidades: specified in variables

;Total;Main;Secondary dwellings;Tool;
Companies that carry out R&D in Biotechnology;1.133;603;173;357;
%Companies according to biotechnology used: Genetic code;33;39;28;25;
%Companies according to biotechnology used: Functional units;41;44;39;36;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;24;29;19;17;
%Companies according to biotechnology used: Bioprocesses;50;45;42;61;
%Companies according to biotechnology used: Sub-cellular organisms;6;8;5;3;
%Companies according to biotechnology used: Bio-computing;24;33;19;12;
%Companies according to biotechnology used: Nanobiotechnology;13;17;15;6;
%Companies according to biotechnology used: Other;14;16;16;11;
%Company by field(s) of ultimate application of biotechnology use: Human Health;45;59;41;24;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;18;21;14;13;
%Company by field(s) of ultimate application of biotechnology use: Food products;31;25;28;43;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;22;19;27;26;
%Company by field(s) of ultimate application of biotechnology use: Environment;14;11;22;13;
%Company by field(s) of ultimate application of biotechnology use: Industry;12;13;16;8;
Personnel in R&D in biotechnology (no. of persons);11.510;6.862;1.521;3.127;
Personnel in R&D in biotechnology (no. of persons): Researchers;6.202;3.759;900;1.543;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;5.308;3.103;621;1.584;
Personnel in R&D in biotechnology (no. of persons): women;6.389;4.015;750;1.624;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;3.304;2.079;442;783;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;3.086;1.937;308;841;
Personnel in R&D in biotechnology (FTE);8.236,9;5.430,2;989,7;1.817;
Personnel in R&D in biotechnology (FTE): Researchers;4.596,1;3.001,4;642,6;952,1;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;3.640,8;2.428,8;347,1;864,9;
Personnel in R&D in biotechnology (FTE): women;4.698,5;3.180,1;503,1;1.015,3;
Personnel in R&D in biotechnology (FTE): (women) Researchers;2.512,5;1.684,7;323,4;504,4;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;2.186;1.495,4;179,7;510,9;
Internal expenditure on R&D (thousands of euros);769.431;541.881;63.951;163.599;
1) By nature of the expense: Current expenses;719.715;502.430;60.603;156.683;
1.1) Remuneration to researchers;221.447;151.282;26.154;44.011;
1.2) Remuneration to technicians and assistants;122.809;83.753;10.469;28.587;
1.3) Other current expenses;375.459;267.396;23.979;84.084;
2) By nature of the expense: Capital expenses;49.715;39.451;3.348;6.916;
2.1) Land and buildings;9.521;7.987;676;858;
2.2) Equipment and instruments;30.466;22.742;2.475;5.248;
2.3) Acquisition of specific R+D software;1.810;1.212;89;509;
2.4) Otros productos de propiedad intelectual específicos para I+D;7.919;7.510;108;301;
1.1) By origin of the funds: Own funds;490.913;347.382;40.321;103.210;
1.2) By origin of the funds: From companies;82.548;62.516;5.356;14.676;
1.3) By origin of the funds: Public Administration funds;96.809;67.645;12.905;16.259;
1.4) By origin of the funds: From Universities;197;193;0;4;
1.5) By origin of the funds: From non profit private institutions;4.766;1.422;0;3.344;
1.6) By origin of the funds: Foreign funds;94.197;62.723;5.369;26.106;
Purchase of R&D services in biotechnology (thousands of euros);120.281;102.804;9.714;7.763;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;69.564;57.335;8.455;3.773;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;50.718;45.469;1.259;3.990;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;45;52;42;35;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;12;9;17;16;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;16;14;20;18;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;14;14;16;12;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of access to international markets;16;16;20;14;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of distribution and sales channels;18;20;18;16;
%Companies that consider the following obstacles as very important considering biotechnology development : Acceptance / public perception;15;15;18;15;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;37;39;38;32;
%Companies that consider the following obstacles as very important considering biotechnology development : Time / cost;52;54;56;46;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;20;20;21;20;
% Companies that have requested biotechnology patents;15;21;11;7;
Number of patents requested;681;485;100;96;
% Companies with income of an international origin related to biotechnological activities;24,3;34,1;12,6;13,5;
% Turnover representing income of an international origin related to biotechnological activities;1;9;0;1;
% Income of of an international origin related to biotechnological activities distributed in: Income received from the EU;59,6;60,2;79,3;54,7;
% Income of of an international origin related to biotechnological activities distributed in: Income received from other countries;40,4;39,8;20,7;45,4;
% Income of of an international origin related to biotechnological activities by classification: Internacional trade in products and services;80,4;78,5;17,9;96,8;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;16,5;19,3;0,6;1,4;
% Income of an international origin related with activities according to the classification: Operating source abroad;2,2;1,3;70,4;1,8;
% Income of an international origin related with activities according to the classification: Other;0,9;0,9;11,1;0;
Notas:
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute